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Abstract
Background: Define covariates of cerebrospinal corticotropin-releasing hormone (CRH) levels
in normal humans. CRHCSF was measured in 9 normal subjects as part of an intensive study of
physiological responses stressors in chronic pain and fatigue states. CRHCSF was first correlated
with demographic, vital sign, HPA axis, validated questionnaire domains, baseline and maximal
responses to pain, exercise and other stressors. Significant factors were used for linear regression
modeling.
Results: Highly significant correlations were found despite the small number of subjects. Three
models were defined: (a) CRHCSF with blood glucose and sodium (explained variance = 0.979,
adjusted R2 = 0.958, p = 0.02 by 2-tailed testing); (b) CRHCSF with resting respiratory and heart
rates (R2 = 0.963, adjusted R2 = 0.939, p = 0.007); and (c) CRHCSF with SF-36 Vitality and
Multidimensional Fatigue Inventory Physical Fatigue domains (R2 = 0.859, adjusted R2 = 0.789, p =
0.02).
Conclusions: Low CRHCSF was predicted by lower glucose, respiratory and heart rates, and
higher sodium and psychometric constructs of well being. Responses at peak exercise and to other
acute stressors were not correlated. CRHCSF may have reflected an overall, or chronic, set-point
for physiological responses, but did not predict the reserves available to respond to immediate
stressors.
Background
Corticotropin – releasing hormone (CRH) plays a major
role in regulating the hypothalamic – pituitary – adrenal
(HPA) axis, acute responses to stressors, and other neuro-
logical functions [1]. The cerebrospinal concentrations of
CRH (CRHCSF) and neuropeptide Y (NPY), another
important neuropeptide involved in pain, autonomic and
stress responses [2,3], were measured in 9 normal humans
to better understand these functions. Subjects were stud-
ied as part of a large scale investigation of subjective and
objective (functional magnetic resonance imaging)
responses to pain testing, exercise, and other stressors [4].
Subjects completed questionnaires that assessed pain,
anxiety, depression, coping skills, and other psychometric
variables. Normal control, fibromyalgia, [5], chronic
fatigue syndrome [6], and veterans of the first Persian Gulf
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War [7] were included. This pilot investigation focuses on
the statistical strategy used to analyze the control popula-
tion (n = 9), and to develop methods for effective evalua-
tion of patient populations. Three multiple linear
regression models [8] were defined that predicted CRHCSF




The mean age for the group was 35.2 yr (95% C.I.: 30.5 to
39.9) years. There were 2 females, 5 African-Americans, 3
Caucasians, and 1 Caucasian Hispanic (TABLE 1). These
subjects were a very normal and healthy group based
upon their histories and the strict exclusion criteria.
NPYCSF
Mean NPYCSF was 121.9 (87.8 to 156.0) pg/ml. NPY did
not correlate with any variable.
Variables correlated with CRHCSF
Significant covariates of CRHCSF could be grouped into:
metabolic, autonomic function, and perceptional and
cognitive functions (TABLE 3). Serum glucose was posi-
tively, and sodium negatively, correlated with CRHCSF
(FIGURE 1). Explained variances (R2) were 0.97 and 0.66,
respectively. Glucose and sodium were also negatively
correlated (R2 = 0.85). Resting norepinephrine levels at 2
time points and heart rate at 4 time points were colinear
and positively correlated to CRHCSF.
Table 1: Physiological data for each individual stratified by CRHCSF
Age (yr) CRHCSF (pg/ml) Sex HRa HRV log p (day)b Heat Scorec Tender points (#) Pressure threshold (kg/cm2)E p i d Norepie
48 32.4 M 76 7.0039 37.7 0 8.32 0 330
31 31.5 F 76 7.128 37.8 0 2.90 0
29 29.7 M 73 7.2561 0 13
35 24 M 68 7.3232 40.5 1 10.11 14 430
31 23.8 M 89 7.2077 0 9.78 20 202
43 19.8 M 48 7.6277 43.9 1 8.67 16 223
25 19.4 M 77 41.4 0 4.76 10 100
36 16 F 76 7.5555 48.8 0 11.71 0 199
39 13.5 M 59 7.3973 43.6 4 7.48 13 182
HRa, heart rate; HRV log p(day)b, log10 of summed daytime heart rate intervals by Holter monitor; Heat Scorec, unpleasantness rating given for the 
first sensation of heat; Epid and Norepie, plasma concentrations of epinephrine and norepinephrine immediately prior to bicycle exercise
Table 3: Significant covariates of CFHCSF in normal subjects.
Co-Variables with CRHCSF rho P N
Glucose @ 2 pm 0.987 0.0018 8
Sodium, mmol/L -0.812 0.0079 9
Norepinephrine, baseline, pre-pain testing 0.790 0.035 7
Norepinephrine 15 min after bike exercise 0.918 0.0035 7
Heart rate, resting, pre-hand grip 0.796 0.018 8
Heart rate, hand grip, 1 min recovery 0.818 0.013 8
Heart rate, hand grip, 2 min recovery 0.747 0.033 8
Heart rate, hand grip, 3 min recovery 0.756 0.049 8
Heart rate, resting, pre-bike exercise 0.825 0.043 6
Heart rate, log, summed for the day -0.810 0.015 8
Pain threshold for hyperthermia -0.844 0.017 8
SF-36 Vitality -0.838 0.0092 8
Self-Efficacy Scale – Manage Symptoms -0.851 0.0073 8
Relationships between CRHCSF, plasma glucose, and serum  sodium Figure 1
Relationships between CRHCSF, plasma glucose, and serum 
sodium. Data from single individuals are shown with identical 
symbols (e.g. solid black squares on left). Open circles indi-
cate sodium without corresponding glucose values. The lin-
ear regression lines for CRHCSF with sodium (top line) and 
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CRHCSF was negatively correlated with the Holter moni-
tor-derived measure of log heart rate summed for the day-
time, and the threshold temperature causing an initial,
mild sensation of burning pain (Stressor I). The latter
indicated that subjects with higher CRHCSF perceived the
burning pain of the cutaneous forearm hyperthermic
stimulation at a lower threshold temperature than their
peers. This may indicate an increased sensitivity to nocic-
eptive stimuli. However, there was no correlation with
deep pressure – induced pain. Negative correlations were
also found with the SF-36 Vitality and SES Manage Symp-
toms domains. High scores were normal for these ques-
tionnaires, with lower scores indicating dysfunction.
Effects in males
All parts of the study were completed by at least 5 males.
Analysis of the male subgroup gave some information
about the role of gender. The pattern of significant covari-
ables was different from the total group (TABLE 4). Respi-
ratory rate was the only vital or physiological sign related
to CRHCSF. Perceptions of vulnerability, physical func-
tioning and self-efficacy were more highly related.
Statistical models
Sets of the significant metabolic, autonomic, and percep-
tual variables were grouped and analyzed by 3 linear
regression models in order to detect significant relation-
ships between independent variables and CRHCSF. The 3
models had high significance levels (TABLE 5). A meta-
bolic model related CRHCSF to glucose and sodium. An
autonomic model linked CRHCSF to resting respiratory
and heart rates. The optimum perceptual model predicted
CRHCSF based on SF-36 Vitality and MFI Physical Fatigue.
The latter 2 domains were not the same as those in
TABLES 3 and 4 because many of these variables were co-
linear or surrogates of one another. This was reinforced by
the similarity of R2 and p values where these domains
were substituted for Vitality and Physical Fatigue. These
results were remarkable because it is very unusual for
models with such small numbers of observations (n ≤ 9)
to be so significant (p < 0.02). The explained variances
were very high (R2 > 0.85) suggesting that the factors may
be causally connected.
CRHCSF did not correlate with variables associated with
maximum exercise, heat – and pressure – (dolorimetry)
induced pain, or other rapid onset stressors (TABLE 1).
Discussion
Despite the small numbers of normal subjects in this pilot
investigation, the data, the explained variances for rela-
tionships, and final 3 models predictive of CRHCSF were
highly significant. The models were of importance, since
they reflected the specific neurological functions of this
neurohormone. CRH and NPY were co-expressed in the
hypothalamus [2], but NPYCSF did not correlate with CRH-
CSF or any other variable.
CRH and the hypothalamic-pituitary-adrenal axis main-
tain numerous systemic functions. Our metabolic model
showed a tightly correlated relationship between 2 pm
serum glucose, sodium and CRHCSF. Relatively higher
CRHCSF levels were associated with elevated serum glucose
levels. When glucose is elevated, it is pumped into cells
along with sodium ions [9]. In our model, this may have
been reflected by the reduced serum sodium concentra-
tions (FIGURE 1). These measurements were taken at dif-
ferent times, suggesting that the CRHCSF set a long-term
operating range for this system. The variables were inter-
related. CRHCSF in the low normal range was inferred from
a low glucose and relatively high sodium. Other reports
also suggest a role of CRH and energy balance [10].
Neuroendocrine responses such as these rely solely on
CRH type 1 (CRH1) receptors and the HPA axis [11]. The
other CRH receptor gene, CRH2, has 3 splice variants (α,
β and γ) but only CRH2α is expressed in the brain. CRH1
and CRH2α receptors have nonoverlapping distributions,
but mediate many similar defensive behaviors suggesting
that they act in parallel neural circuits. Different stressors
may act by separate circuits and have distinct feedback
and control systems [11-13]. CRH1 receptors in the
central nucleus of the amygdala may participate in condi-
tioned fear responses [12]. These CRH neurons may
project to the hippocampus and CRH1 receptors in the
locus ceruleus to induce defensive behaviors and auto-
nomic reflexes [13,14]. Dorsal raphe nucleus neurons
may release CRH that acts on inhibitory CRH2α receptors
in the lateral septum [15]. Neurons from the lateral sep-
tum tonically inhibit periaqueductal grey regions that
induce similar defensive behaviors. These nuclei are prob-
ably additional sources of CRH in the CSF.
Table 4: Significant covariates of CFHCSF and relevant statistics 
in males.
Co-Variables with CRHCSF Rho P N
Respiratory Rate 0.953 0.0009 7
MIQ Vulnerability -0.911 0.031 5
MFI Physical Functioning -0.909 0.032 5
SF-36 Change in Health -0.887 0.044 5
Self-efficacy – manage symptoms -0.853 0.030 6BMC Neuroscience 2004, 5:58 http://www.biomedcentral.com/1471-2202/5/58
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Resting respiratory and pre-exercise heart rates and CRH-
CSF were positively correlated. The statistical model indi-
cated that a low CRHCSF was predicted by low respiratory
and heart rates. Respiratory and cardiac functions are rig-
orously controlled by brainstem and other nuclei that
integrate incoming signals of plasma O2, CO2 and H+ con-
centrations, activity needs, anxiety and other stressors.
Efferent cardiovascular and other autonomic reflexes are
modulated by CRH in man [16]. These central nervous
system effects may be due to, or highly correlated with,
CRHCSF. This is supported by studies in mice that geneti-
cally overexpress CRH. They develop chronic stress – like
autonomic and physiological alterations [17]. Stressors
acting via conditioned fear responses may involve CRH1
receptors in the central nucleus of the amygdala. Some of
these CRH neurons project to locus ceruleus neurons [17]
that activate autonomic reflexes and defensive behaviors
such as "freezing" (immobility) in rodents [14]. An exam-
ple of this valuable defense would be the freezing of prey
in the presence of a predator. Immobility would allow the
prey's camouflage to blend into the surroundings without
generating motion – induced visual cues for the predator.
In humans, excessive, aberrant or dysregulated manifes-
tions of defense behaviors such as freezing may contribute
to the immobility, inertia, or even catatonia that contrib-
ute to the clinical picture of depression [1].
Extrapolation of these concepts suggests that elevated
CRH may be related to anxiety, depression, or other disor-
ders associated with chronic stress responses. If so, then
lower, but normal, CRHCSF should be present in persons
lacking these stressor states. This was supported by the
negative correlations of CRHCSF with scores for the SF-36
Vitality and Change in Health, Self Efficacy Scale Manage
Symptoms, MIQ Vulnerability, and MFI Physical Func-
tioning domains. Each scale has an idealized "normal"
end of the range of scores. Deviation towards either higher
(MFI) or lower (SF-36) ends of the scales provides an esti-
mate of dysfunction. For each of these domains, the lower
CRHCSF were associated with more normal scores, while
higher CRHCSF was associated with scores that were begin-
ning to shift away from the normal pole of each scale.
These trends were further supported by the statistical
model where the optimum covariates of CRHCSF were SF-
36 Vitality and MFI Physical Fatigue domains. The model
predicted that CRHCSF would be in the low normal range
when Vitality and Physical Fatigue domain scores were
high (normal). Taken together, these results confirm the
consistent physical status, mental coping skills, and gen-
eral health of these subjects.
Studies of intraventricular CRH injection in primates sup-
port our findings [33]. The CRH diffused to brain regions
that led to 3 types of behavioral changes. Externally ori-
ented behaviors such as locomotion and environmental
exploration were significantly decreased. Anxiety – related
self – clasping was increased. Depression – like behaviors
of avoidance of social contact, huddling, slouching, and
wall facing were seen only in social settings. There were
high interindividual differences in responses, but a key
element was the social context in this study. This social
context is lacking in rodent studies where animals are typ-
ically studied in isolation.
Conclusion
This small but intensively studied group of normal
humans demonstrated surprisingly robust relationships
between CRHCSF and metabolic, autonomic, and psycho-
metric measures. These are novel findings in humans, but
are consistent with data on CRH in acute and chronic
stress models, and proposed CRH neural circuits. It will
now be of great interest to contrast these statistical models
identified for normal subjects with the other chronic pain
and fatigue patient subsets to determine if CRHCSF corre-
lates with different sets of variables.
Methods
Subjects
Nine normal, healthy subjects (2 females) gave informed
consent for this paid, Institutional Review Board –
approved protocol. They had a comprehensive screening
evaluation to exclude: severe physical impairment, mor-
bid obesity, autoimmune/inflammatory diseases, cardi-
opulmonary disorders, uncontrolled endocrine or allergic
disorders, malignancy, severe psychiatric illnesses (e.g.,
Table 5: Linear regression models of CRHCSF
Components of 3 Linear Regression Models R2 (adjusted R2) * P ** DoF ***
CRHCSF, Glucose @ 2 pm, serum Sodium (mmol/L) 0.979 (0.958) 0.02 4
CRHCSF, Respiratory Rate, Resting Heart Rate 0.963 (0.939) 0.007 7
CRHCSF, SF-36 Vitality, MFI Physical Fatigue 0.859 (0.789) 0.02 6
* R2 = expected variance; ** P = 2 tailed probability for the model; *** Degrees of freedomBMC Neuroscience 2004, 5:58 http://www.biomedcentral.com/1471-2202/5/58
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schizophrenia, substance abuse), factors known to affect
the HPA axis or autonomic function (cigarette smoking,
daily intake of caffeine exceeding the equivalent of 2 cups
of coffee), or medication use. Subjects had a history and
physical examination, were administered the Structured
Clinical Interview for the Diagnostic and Statistical Man-
ual of Mental Disorders, fourth edition (DSM-IV) (SCID
II) [19,20], Composite International Diagnostic Interview
(CIDI) [21,22] and Center for Epidemiologic Studies
Depression scale (CESD) [23] to detect psychiatric co-
morbidities, and completed the self – report Short Form
36 (SF-36) [24,25], Self Efficacy Scale (SES) [26], Meaning
of Illness Questionnaire (MIQ) [27], and Multidimen-
sional Fatigue Inventory (MFI) [28].
Study protocol
Subjects were admitted to the G-CRC on the evening of
Day 1. An 18-gauge catheter was inserted antecubitally
and infused with normal saline at 50 ml/hr. A Holter
monitor was attached to monitor autonomic regulation of
cardiac rhythm [29-31]. Upon awakening, or at 6:30 am,
subjects stayed in bed until they had "pre-awakening"
blood tests drawn. Breakfast was served between 7:00 and
8:00 a.m. and baseline Day 2 blood samples drawn at
8:30 a.m. Vital signs, questionnaire responses, and other
blood samples were drawn from the catheter to assess
HPA axis and stress system responses before, during and
after Day 2 stressors. Pain responses were tested by pres-
sure applied to each subject's thumbnail and heat to the
forearm applied in random staircase testing paradigms
(Stressor I) [32,33]. Stressor II was a series of cognitive
challenges including the Benton Visual Retention Test of
visual-spatial memory; Digit Span recitation; and Pig
Latin, a test of verbal working memory [34]. Lunch was
served, followed by a 2 to 2.5 hours rest break to allow
post-prandial catecholamine levels to reequilibrate. At 2
pm, serum glucose, electrolytes, plasma catecholamines
and other analytes were measured. Subjects then squeezed
an isometric hand grip dynamometer to test autonomic
function and muscular fatigue [35] (Jamar, Sammons
Preston, Bollingbrook, IL) (Stressor III). After 30 min of
rest, they had a sub-maximal exercise test on an electroni-
cally-braked cycle ergometer (Sensormedics, Yorba Linda,
CA). The test was graded in 3 min stages and ended when
the subjects' heart rates reached 85% of their age-pre-
dicted maximum (Stressor IV). Lumbar punctures were
performed 30 min later (approximately 4 pm) (Stressor
V). Subjects sat while sterile technique was used to prepare
the skin over the L4–L5 lumbar region, infiltrate the sub-
cutaneous and deep tissues with 2% lidocaine, and insert
a 22G spinal catheter. CSF was collected as 3 to 4 aliquots
of about 2 ml each. Catheters were withdrawn and sub-
jects allowed to rest in their preferred position for 30 min.
Lumbar punctures and CRH and NPY radioimmunoassays 
(RIA)
Tubes of CSF were immediately placed on ice and then
centrifuged at 4°C. The supernatants were rapidly frozen
at -80°C. Tube 2 or 3 was removed from the freezer and
thawed at 4°C. Peptides were extracted by precipitating
high molecular weight proteins by adding an equal vol-
ume of 100% ethanol, 0.1 M acetic acid, 0.2% sodium
bisulfite [36,37]. The supernatant was dried (SpeedVac,
Thermo Savant, Holbrook, NY), resuspended in phos-
phate buffered saline with 1% bovine serum albumin
(RIA buffer; Peninsula Laboratories, Inc., San Carlos,
CA.). Samples and standard amounts of each peptide were
aliquoted and peptide specific rabbit antibodies added.
After overnight incubation at 4°C, I125-CRH or -NPY was
added, tubes gently vortexed, and again incubated over-
night. Goat anti-rabbit antibodies were added, tubes incu-
bated, and immune complexes precipitated by
centrifugation. Radioactivity was counted for the stand-
ards, and the concentrations for each sample interpolated
from the standard curves. Spiking CSF with fixed amounts
of I125-peptides and performing the RIA shifted the curves
to the left by the anticipated concentrations. Standard
curves were reproducible to within 10%.
Plasma catecholamine levels were measured by HPLC
(Mayo Clinic Laboratories, Rochester, MN).
Statistical methods
All the data from the provocation studies, questionnaire
domains, blood work, and neuropeptide analysis were
entered into a SAS spreadsheet (SAS, Carey, NC) using
sequential hand or scanner entry followed by data check-
ing routines.
Means with 95% confidence intervals were reported.
Simple correlations between our outcome measure (CRH-
CSF) and other objective and subjective patient variables
were conducted as an exploratory tool. Given the small
sample size (n = 9), both parametric and non-parametric
correlations were used to evaluate the robustness of the
correlation coefficients. Partial and intra-class correlations
examined the structure of the relationships between CRH-
CSF and the independent variables. Original data were
always checked to make sure that correlations were not
spurious, due to outliers, colinearity, or sets of virtually
identical scores.
Our data included a very wide range of covariates which
spanned the physical and psychological attributes of the
patients. Scatter plots were used to determine the response
slopes with CRHCSF. Independent variables with flat
slopes or high scatter that did not generate correlations
with CRHCSF, that were highly correlated with each otherBMC Neuroscience 2004, 5:58 http://www.biomedcentral.com/1471-2202/5/58
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(collinear), or that had < 5 recorded values were excluded
from further analysis.
The remaining suitable independent variables fell into 3
categories: metabolic, autonomic and psychometric func-
tion. Three 3 separate linear regression models [8] were
constructed to predict CRHCSF, the dependent variable.
Separate models were required because of the low degrees
of freedom available for the analyses, and to ensure that
the explained variance (R2) was not inflated due to over-
loading the model with potentially collinear variables.
Variance inflation factors and tolerance values were incor-
porated to optimize the selection of the most independ-
ent combinations of variables that also maximized the R2
and p values. The linear regression procedure took into
account the multiple comparisons for each model.
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